Forskolin/rolipram - Innomedica

Drug Profile

Forskolin/rolipram - Innomedica

Alternative Names: Rolipram/forskolin; TLFR

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InnoMedica
  • Developer InnoMedica; University of Hawaii
  • Class Antihyperlipidaemics
  • Mechanism of Action Adenylate cyclase stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Atherosclerosis

Most Recent Events

  • 22 May 2017 Suspended - Preclinical for Atherosclerosis in Switzerland (Liposomal) (InnoMedica communication, May 2017)
  • 11 May 2017 Chemical structure information added
  • 12 Dec 2015 Preclinical trials in Atherosclerosis in Switzerland (Liposomal) (Innomedica pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top